Aytu Biopharma Inc (AYTU)

Panoramica Notizia Cronologia dei prezzi Financials Perché AYTU Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Aytu Biopharma Inc Stock (AYTU) Company Profile

Aytu Biopharma Inc

Healthcare (1111)

(720) 437-6580

7900 E. UNION AVENUE, DENVER

@aytubioscience

Prossima data di guadagno

Ultimi documenti SEC

AYTU's Discussions on Twitter

Confronta AYTU con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AYTU Aytu Biopharma Inc	2.60	26.29M	66.38M	-14.18M	-5.17M	-2.8074
ZTS Zoetis Inc	124.82	53.64B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	17.23	54.24B	29.85B	776.90M	4.35B	0.2408
HLN Haleon Plc Adr	10.47	45.87B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	34.08	37.94B	17.39B	1.43B	774.28M	1.219
UTHR United Therapeutics Corp	469.49	20.14B	3.13B	1.27B	1.12B	26.39

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-01	Iniziato	Lake Street	Buy
2025-06-30	Iniziato	Ascendiant Capital Markets	Buy
2021-03-30	Iniziato	Cantor Fitzgerald	Overweight
2020-05-29	Iniziato	H.C. Wainwright	Buy

Aytu Biopharma Inc Borsa (AYTU) Ultime notizie

Aytu Biopharma Inc Azioni (AYTU) Dati Finanziari

Aytu Biopharma Inc (AYTU)

Aytu Biopharma Inc Stock (AYTU) Company Profile

Confronta AYTU con altri titoli

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Aytu Biopharma Inc Borsa (AYTU) Ultime notizie

Gainers Report: Will Aytu BioPharma Inc stock benefit from M A2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 - ACCESS Newswire

Pharma News: Will Aytu BioPharma Inc benefit from rising consumer demandQuarterly Market Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn

Aytu launches EXXUA, first selective 5-HT1A agonist for depression By Investing.com - Investing.com South Africa

Aytu BioPharma Highlights EXXUA Opportunity at Investor Day - TipRanks

Aytu BioPharma Recaps Investor Day Held on January 20, 2026 - ACCESS Newswire

Aytu BioPharma Recaps Investor Day and EXXUA Launch - TradingView

New EXXUA depression drug targets MDD without sexual side effects - Stock Titan

AYTU: Exxua launches as a differentiated MDD therapy, targeting growth with disciplined, scalable execution - TradingView

AYTU: Exxua launches as a novel MDD therapy, targeting unmet needs with strong financial discipline - TradingView

Aytu launches EXXUA, first selective 5-HT1A agonist for depression - Investing.com

Aytu BioPharma (AYTU) Launches EXXUA for Treating Major Depressi - GuruFocus

Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Di - PharmiWeb.com

Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA - ACCESS Newswire

New depression drug EXXUA avoids sexual dysfunction and weight gain - Stock Titan

Will Aytu BioPharma Inc. (AY20) stock outperform global peersREITs Market Trends & Small Investment Big Gains - Bollywood Helpline

Aytu BioPharma Talks Exxua MDD Launch, Differentiation and RxConnect Access at Investor Summit - Defense World

AYTU: Exxua's launch leverages unique differentiation and RxConnect to target major growth in depression treatment - TradingView — Track All Markets

Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 - ACCESS Newswire

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City - ACCESS Newswire

How Aytu BioPharma Inc. (AY20) stock reacts to fiscal policiesJuly 2025 Technicals & Stepwise Swing Trade Plans - ulpravda.ru

Buybacks Report: Is Aytu BioPharma Inc. stock dividend yield sustainableForecast Cut & Daily Volume Surge Signals - Улправда

Portfolio Recap: How sustainable is Aytu BioPharma Inc. stock dividend payoutQuarterly Market Summary & AI Enhanced Trading Alerts - Улправда

Why Aytu BioPharma Inc. stock attracts high net worth investorsMarket Risk Report & High Accuracy Trade Alerts - Улправда

Will Aytu BioPharma Inc. stock outperform tech sector in 2025July 2025 Sentiment & High Conviction Investment Ideas - Улправда

Why Aytu BioPharma Inc. stock is favored by top institutionsTreasury Yields & Comprehensive Market Scan Reports - ulpravda.ru

Entry Recap: Why Aytu BioPharma Inc. stock attracts high net worth investorsPortfolio Gains Summary & Weekly Top Stock Performers List - Улправда

Aytu BioPharma (AYTU) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Published on: 2025-12-24 03:59:28 - moha.gov.vn

Can Aytu BioPharma Inc. stock sustain revenue growthJuly 2025 Outlook & Capital Efficiency Focused Strategies - Улправда

Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st

Is Aytu BioPharma Inc. stock attractive for income investors2025 Winners & Losers & Low Risk High Win Rate Picks - Улправда

Aytu BioPharma announces commercial availability of EXXUA tablets - MSN

Will Aytu BioPharma Inc. stock deliver shareholder valueTrade Performance Summary & Low Drawdown Trading Strategies - DonanımHaber

How sustainable is Aytu BioPharma Inc. stock dividend payoutEarnings Growth Summary & Safe Capital Allocation Plans - DonanımHaber

Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City - ACCESS Newswire

Depression drug EXXUA takes center stage at New York investor event - Stock Titan

Aytu BioPharma launches depression drug EXXUA in U.S. market - Investing.com India

Aytu BioPharma launches depression drug EXXUA in U.S. market By Investing.com - Investing.com Nigeria

Aytu BioPharma stock rises after commercial launch of depression drug EXXUA - Investing.com Canada

Aytu BioPharma (AYTU) Launches EXXUA for Major Depressive Disorder in U.S. - GuruFocus

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults - Times Argus

Aytu BioPharma (Nasdaq: AYTU) makes EXXUA depression drug commercially available in US - Stock Titan

Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome - ACCESS Newswire

AWM Investment Company Inc. Takes $1.35 Million Position in Aytu BioPharma Inc. $AYTU - Defense World

Aytu BioPharma (NASDAQ:AYTU) Given New $13.00 Price Target at Ascendiant Capital Markets - Defense World

Aytu Biopharma Inc Azioni (AYTU) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Simile a AYTU